A phase I open label, dose escalation trial to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CE-245,677, an oral TIE2 kinase inhibitor, in patients with advanced solid tumors
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2007
At a glance
- Drugs CE 245677 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 22 Feb 2007 New trial record.